alexa
Reach Us +44-1647-403003
The Choice of the Endpoint to Assess the Efficacy or Effectiveness in Advanced or Metastatic Cancer Tumors | OMICS International | Abstract
ISSN: 1948-5956

Journal of Cancer Science & Therapy
Open Access

Like us on:

Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Review Article

The Choice of the Endpoint to Assess the Efficacy or Effectiveness in Advanced or Metastatic Cancer Tumors

Takayoshi Kiba*

Division of Modern Medical Technology, Institute for Clinical Research, National Hospital Organization Kure Medical Center, Kure, 737-0023

*Corresponding Author:
Dr. Takayoshi Kiba, MD, PhD
Division of Modern Medical Technology
Institute for Clinical Research
National Hospital Organization Kure Medical Center
Kure, 737-0023, Hiroshima, JAPAN
Tel: 81±4-7137-3737
E-mail: [email protected]

Received Date: March 09, 2011; Accepted Date: September 08, 2011; Published Date: September 11, 2011

Citation: Kiba T (2011) The Choice of the Endpoint to Assess the Efficacy or Effectiveness in Advanced or Metastatic Cancer Tumors. J Cancer Sci Ther 3:154-157. doi: 10.4172/1948-5956.1000079

Copyright: © 2011 Kiba T. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Abstract

It is important to investigate whether other clinical endpoints, such as response rate, disease stabilization rate, or progression free survival could replace overall survival as the primary endpoint for the patients with advanced or metastatic cancer. Before a surrogate end point can replace a so-called 'true' end point of interest, it must be formally validated, a process that has caused considerable controversy in the past two decades. The aim of this review manuscript is to discuss some of the limitations encountered when survival is used as the primary study end point for evaluating the efficacy or effectiveness in phase II or III trials for advanced or metastatic cancer tumors.

Keywords

Share This Page
Top